<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="//revista.sboc.org.br/wp-content/plugins/wordpress-seo/css/main-sitemap.xsl"?>
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-image/1.1 http://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
	<url>
		<loc>https://revista.sboc.org.br/sboc-review/novo-adc-supera-quimioterapia-em-carcinoma-de-nasofaringe-avancado-politratado/</loc>
		<lastmod>2026-03-13T13:02:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://revista.sboc.org.br/sboc-review/pembrolizumabe-mais-lenvatinibe-no-carcinoma-ginecologico-de-celulas-claras-recorrente-lara-um-estudo-multicentrico-de-braco-unico-fase-2/</loc>
		<lastmod>2026-03-13T13:05:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://revista.sboc.org.br/sboc-review/trastuzumabe-deruxtecana-neoadjuvante-isolado-ou-seguido-de-paclitaxel-trastuzumabe-e-pertuzumabe-no-cancer-de-mama-inicial-her2-positivo-de-alto-risco-destiny-breast11-estudo-fase-iii-randomiza/</loc>
		<lastmod>2026-03-13T13:10:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://revista.sboc.org.br/sboc-review/enfortumabe-vedotina-e-pembrolizumabe-perioperatorios-no-cancer-de-bexiga-%e2%96%b6-comentario-em-video/</loc>
		<lastmod>2026-03-13T14:26:16+00:00</lastmod>
	</url>
</urlset>
<!-- XML Sitemap generated by Yoast SEO -->